BMI1 gene expression in myeloid leukemias and its impact on prognosis

Blood Cells, Molecules, and Diseases

Volumn 53, Issue 4, 2014, Pages 194-198

  Saudy, Niveen S ^a   Fawzy, Iman M ^b   Azmy, Emad ^a   Goda, Enas F ^a   Eneen, Asmaa ^a   Abdul Salam, Eman M ^c  

^a MANSOURA UNIVERSITY   (Egypt)

^b MINISTRY OF HEALTH   (Egypt)

^c AL AZHAR UNIVERSITY   (Egypt)

Author keywords

AML; BMI1; CML; Leukemia; Myeloid; Polycomb

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BMI1 GENE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; CASE CONTROL STUDY; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; SURVIVAL;

BMI1 PROTEIN; BMI1 PROTEIN, HUMAN;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYCOMB REPRESSIVE COMPLEX 1; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84908099293     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.07.002     Document Type: Article

References (25)

1. Radulović V., de Haan G., Klauke K. Polycomb-group proteins in hematopoietic stem cell regulation and hematopoietic neoplasms. Leukemia 2013, 27:523-533.
2. Sawa M., Yamamoto K., Yokozawa T., Kiyoi H., Hishida A., Kajiguchi T., Seto M., Kohno A., Kitamura K., Itoh Y., Asou N., Hamajima N., Emi N., Naoe T. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int. J. Hematol. 2005, 82:42-47.
3. Chowdhury M., Mihara K., Yasunaga S., Ohtaki M., Takihara Y., Kimura A. Expression of polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 2007, 21:1116-1122.
4. Bhattacharyya J., Mihara K., Yasunaga S., Tanaka H., Hoshi M., Takihara Y. BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia. Ann. Hematol. 2009, 88:333-340.
5. Qin Z.K., Yang J.A., Zhou F.J., Han H., Liu Z.W., Yu S.L., Li Y.H., Chen Z.F. Expression and clinical significance of Bmi-1 protein in bladder cancer. Chin. J. Cancer 2008, 27(12):574-577.
6. Schuringa J.J., Vellenga E. Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells. Curr. Opin. Hematol. 2010, 17:294-299.
7. Perez D.M., Piris M.A., Beato M.S. Polycomb proteins in hematologic malignancies. Blood 2010, 116:5465-5475.
8. Kim J.H., Yoon S.Y., Kim C.N., Joo J.H., Moon S.K., Choe I.S., Choe Y.K., Kim J.W. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004, 203:217-224.
9. Xu F., Yang R., Wu L., He Q., Zhang Z., Zhang Q., Yang Y., Guo J., Chang C., Li X. Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome. Cancer Lett. 2012, 317:33-40.
10. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and polycombgroup gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
11. Schoch C., Kern W., Schnittger S., Hiddemann W., Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004, 18:120-125.
12. Dahiya A., Wong S., Gonzalo S., Gavin M., Dean D.C. Linking the Rb and polycomb pathways. Mol. Cell 2001, 8:557-569.
13. van Kemenade F.J., Raaphorst F.M., Blokzijl T., Fieret E., Hamer K.M., Satijn D.P., Otte A.P., Meijer C.J. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001, 97:3896-3901.
14. Mihara K., Chowdhury M., Nakaju N., Hidani S., Ihara A., Hyodo H., Yasunaga S., Takihara Y., Kimura A. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 2006, 107:305-308.
15. Dybko Jarosław, Jaźwiec Boz˙ena, Kuliczkowski Kazimierz Coexpression of BMI-1 and interleukin-3 receptor alpha chain (CD123) correlate with poor prognosis acute myeloid leukemia. AcademyPublish.org. J. Eng. Technol. 2013, 2:92-102.
16. Mohty M., Yong A.S., Szydlo R.M., Apperley J.F., Melo J.V. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007, 110:380-383.
17. Beà S., Tort F., Pinyol M., Puig X., Hernández L., Hernández S., Fernandez P.L., van Lohuizen M., Colomer D., Campo E. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001, 61:2409-2412.
18. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-752.
19. Marin D., Milojkovic D., Olavarria E., Khorashad J.S., de Lavallade H., Reid A.G., Foroni L., Rezvani K., Bua M., Dazzi F., Pavlu J., Klammer M., Kaeda J.S., Goldman J.M., Apperley J.F. European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437-4444.
20. Merkerova M., Bruchova H., Kracmarova A., Klamova H., Brdicka R. Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation. Leuk. Lymphoma 2007, 48:793-801.
21. Proctor E., Waghray M., Lee C.J., Heidt D.G., Yalamanchili M., Li C., Bednar F., Simeone D.M. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS One. 2013, 8:e55820.
22. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
23. Rizo A., Horton S.J., Olthof S., Dontje B., Ausema A., van Os R., van den Boom V., Vellenga E., de Haan G., Schuringa J.J. BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34 cells. Blood 2010, 116:4621-4630.
24. Sengupta A., Ficker A.M., Dunn S.K., Madhu M., Cancelas J.A. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Blood 2012, 119:494-502.
25. Oguro H., Yuan J., Tanaka S., Miyagi S., Mochizuki-Kashio M., Ichikawa H., Yamazaki S., Koseki H., Nakauchi H., Iwama A. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J. Exp. Med. 2012, 209:445-454.